Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

Bicycle Therapeutics targets innovative cancer treatments with potential, like zelenectide pevedotin. Read here for an ...

D modeling for robotic prostatectomyCost comparison of checkpoint inhibitors in high-risk bladder cancerAI-generated prostate ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...